First-in-human trial to study remestemcel-L as Crohn’s disease therapy launched
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
List view / Grid view
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
A new report has shown that through the COVID-19 pandemic, the global nasal drug delivery technology market is predicted to increase.
Researchers have shown that mucoadhesive buccal films containing simvastatin inclusion complex and drug mixed micelles can improve the drug's bioavailability.
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
A Phase I clinical trial to test an intranasal COVID-19 vaccine spray has been given regulatory approval in China and is expected to begin in November.
A clinical trial has shown that antibiotics administered orally are just as effective at killing Pseudomonas aeruginosa in cystic fibrosis patients as intravenous antibiotics.
The implanted biomaterial drug delivery system releases methylprednisolone and reduces inflammation, promoting central nervous system (CNS) repair.
This whitepaper explores critical factors for over-encapsulation success. DBcaps® capsules offer a convenient option for blinding in clinical trials.
Performance of orally disintegrating tablets (ODTs) with GRANFILLER-D was investigated by the real-time X-ray observation of water penetration into ODTs.
This application note explores how BD is dedicated to deliver best-in-class product performance and services by applying the latest advances in drug delivery technology.
Kesimpta was approved based on trial results showing the monthly injection significantly reduced the relapse rate and disability progression of MS patients compared to a currently approved treatment.
This whitepaper studies the effect of humidity on tablet surfaces containing different types of super disintegrants.
Superdisintegrants are categorised by their mechanism of action such as wicking, swelling or shape recovery. In this study, the performance of disintegrants from each of these groups was tested in an insoluble, hydrophobic tablet formulation.
Watch how PROSOLV® EASYtab, the all-in-one excipient composite, offers superior disintegration for your tablet formulations.
Discover JRS PHARMA's industry leading manufacturing network for Microcrystalline Cellulose.